Published in Medical Letter on the CDC and FDA, May 16th, 2010
"In the first months of 2010, we have continued to make excellent progress toward the commercialization of BENLYSTA," said H. Thomas Watkins, President and Chief Executive Officer. "BENLYSTA met the primary efficacy endpoint in both of its pivotal Phase 3 trials, with results that support our belief that this first-in-class treatment could become the first new approved drug for lupus in more than 50 years. For ZALBIN dosed once a month, we reported positive interim results from a Phase 2b trial that appear to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA